National
Victory Institute executive director speaks about movement response to Trump 2.0
Advocacy groups will lead efforts to push back against anti-LGBTQ administration
President Donald Trump’s issuance of a series of executive orders targeting transgender rights and LGBTQ-inclusive diversity programs on the first day of his second term was a clear signal of the new administration’s appetite for going after queer and gender diverse people.
The Jan. 20 directives also brought into focus the extent to which organizations in the LGBTQ movement, particularly those whose work includes impact litigation, will be responsible for protecting the communities they serve from harmful and discriminatory laws and policies over the next four years.
At a critical time that is likely to test the limits of their capacity, these groups are facing challenges that could restrict their access to critical resources thanks in part to the conservative movement’s opposition to diversity, equity, and inclusion in both government and the private sector.
LGBTQ organizations expected federal funding for their work would dry up when the incoming administration took over, given that Trump and his allies made no secret of their plans to aggressively reshape the government including by ridding U.S. agencies of all DEI-related programs, policies, and activities.
Trump went even further, however, issuing orders to categorically freeze the disbursement of government funds tied to preexisting grants and contracts, while threatening investigations of private companies for “illegal” policies and practices related to DEI.
Partly in response to pressure from conservative leaders and activists, over the past couple of years companies have increasingly backed away from DEI efforts including, especially, support for LGBTQ communities and causes.
Coupled with the loss of federal funding, a decline in corporate giving to LGBTQ organizations could have devastating impacts on the communities they serve, potentially leading to cutbacks in programs and services core to their missions or imperiling their efforts to push back against a hostile regime.
“Continuing to fund our work is obviously top of mind for everyone right now,” Elliot Imse, executive director of the LGBTQ+ Victory Institute, told the Washington Blade during an interview last week.
The move by many private companies away from supporting LGBTQ equality has been surprising, Imse said, but “what we know is it’s a very uncertain environment for corporations right now, and they are feeling out these new realities.”
On the other hand, the moment also presents an opportunity to remind businesses that commitments to DEI are good for their bottom line while rewarding companies that resist pressure to abandon their LGBTQ customers, employees, and communities, Imse said.
“There’s a lot of courageous corporations out there, too, right now, a lot that are continuing to step up. And we need to be grateful; we need to be making purchasing decisions as a community with those corporations in mind. Every corporation that has reaffirmed its commitment to us, we need to go out and support them.”
“While Victory Institute — like all LGBTQ+ organizations — is concerned about the current fundraising environment, we have a programmatic plan in place that directly addresses the realities of what is happening across the country right now,” he said, with programs to support LGBTQ elected officials serving everywhere from small municipal offices to the most powerful positions in government.
A diverse pipeline of out leaders from diverse backgrounds is the best bulwark “against attacks on our equality and democratic backsliding,” Imse said. “We have a very robust programmatic plan for 2025 — and we need to execute on it at this critical moment.”
While the Victory Institute is currently looking for funding to support the organization’s international work to compensate for the loss of federal grants, Imse said the group plans to expand U.S.-based programs, maximizing their reach at a time when this work is especially critical.
“We’re going to be in more cities than ever before. We’re going to have a larger training presence than ever before, including our LGBTQ+ Public Leadership Summits, which are specifically designed to inspire and recruit LGBTQ+ people to run for office. It is essential folks reject the demoralization of the current moment and that we have more boots on the ground to support those willing to step up and run.”
He added, “we are hopeful that we will be able to raise the money we need to carry these programs out, and we believe we can make the case to donors that these programs are an essential path forward.”
At the same time, Imse acknowledged that LGBTQ groups, including the Victory Institute, are in a difficult position at the moment and “we’ll absolutely have to adjust if we see a downturn in fundraising throughout the year.”
“it’s going to be an uphill battle, there’s no doubt about that. Like all other organizations, we’re going to watch the numbers and adjust as necessary,” he said, adding, “the people we have at our organization are what makes our organization strong — their expertise, their relationships, the networks that they’ve built.”
And while he said “making sure that we meet the moment is something that keeps me up at night,” Imse stressed that “figuring out how to balance the reality we are in versus optimism is something that is on everyone’s mind as you talk to LGBTQ+ community members, your staff, your funders” who recognize that “you must have hope, because if people back away from our equality at this moment, it’ll be much worse than even the situation we’re in right now.”
There is no shortage of good reasons to hold onto hope, Imse said. “Our movement has always thrived in moments of crisis. While we’d prefer no crisis, it refocuses us. It motivates us. And oftentimes leads to breakthroughs that we may not have had otherwise. It destroys complacency. It instills urgency.”
After Trump took office and the new Congress was sated with GOP majorities in both chambers, LGBTQ groups whose work includes lobbying or government relations understood their ability to influence policy at the federal level would be limited, at least until Democratic allies have the opportunity to retake control of the House in 2026.
The Victory Institute was especially well positioned to shift away from Washington, Imse said, because state legislatures, city councils, and school boards have always been the organization’s “bread and butter” and the elections for these positions “truly matter” even if they are less “high profile” than U.S. congressional races.
“When we’re talking about opportunities to make progress in the near future, opportunities to launch a successful offense and defense, it is in these legislative bodies,” he said. “And they arguably make more impact on individuals’ lives than the federal government does.”
Imse added this is especially true with regard to opportunities for legislative action to support LGBTQ Americans and defend their rights, which is unlikely to happen on Capitol Hill for a “long time.”
It is especially important now that LGBTQ communities and organizations support each other, he said.
LGBTQ movement groups, particularly those with international focus, “have been phenomenal in bringing us together and trying to find out what’s been done, keeping us up to date on potential litigation opportunities, as well as looking for funders that are willing to step up at this absolutely critical moment in our movement’s history,” Imse said.
“We also need our community to step up in terms of supporting these organizations,” he said, “financially through resources and capacity and giving their time, because that’s the only way we’re going to be able to move forward effectively.”
It is “important that our community members remain active, engaged, and involved, and that our LGBTQ+ media continues to ensure our stories are being told,” Imse said, adding, “Especially right now, this is an entire movement ecosystem that is working to make sure whatever backsliding is about to occur is not permanent.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Protecting the trans community is not optional for elected allies and candidates
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
